Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
16.10
Nov 19 • 3:59 PM ET Dollar change-0.15 Percentage change(-0.92%)
Aftermarket Close
16.10
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
3.12B
Enterprise Value
2.44B
Income
-0.32M
Sales
1.36B
Book/sh
6.56
Cash/sh
4.39
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
2900
IPO
Jun 05, 2020
P/E
-
Forward P/E
33.03
PEG
-
P/S
2.29
P/B
2.45
P/C
3.66
P/FCF
-
EV/EBITDA
27.58
EV/Sales
1.79
Quick Ratio
3.82
Current Ratio
3.95
Debt/Eq
0.13
LT Debt/Eq
0.09
Option/Short
Yes / Yes
EPS (ttm)
-0.03
EPS next Y
0.49
EPS next Q
0.05
EPS this Y
110.14%
EPS next Y
493.73%
EPS next 5Y
-
EPS past 3/5Y
16.80% 6.49%
Sales past 3/5Y
106.67% 68.87%
EPS Y/Y TTM
98.75%
Sales Y/Y TTM
49.73%
EPS Q/Q
220.35%
Sales Q/Q
32.18%
Insider Own
4.60%
Insider Trans
-0.43%
Inst Own
50.71%
Inst Trans
-3.67%
ROA
-0.02%
ROE
-0.03%
ROIC
-0.02%
Gross Margin
53.28%
Oper. Margin
2.79%
Profit Margin
-0.02%
SMA20
-20.24%
SMA50
-16.31%
SMA200
-27.40%
Trades
Shs Outstand
193.97M
Shs Float
185.04M
52W High
37.50 -57.07%
52W Low
15.75 2.22%
Volatility
6.98% 6.92%
ATR (14)
1.34
RSI (14)
34.16
Beta
0.63
Rel Volume
1.06
Avg Volume
2.24M
Volume
2,367,546
Perf Week
-13.16%
Perf Month
-13.58%
Perf Quarter
-26.21%
Perf Half Y
-42.48%
Perf YTD
-25.94%
Perf Year
-42.50%
Perf 3Y
-75.06%
Perf 5Y
-70.86%
Perf 10Y
-
Prev Close
16.25
Price
16.10
Change %
-0.92%
Consensus
Buy
Avg. Price Target
$41.13
Implied Upside
+155.5%
Analysts16incl. previous ratings
Rating Distribution9 Buy · 7 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 16, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line$20+24.2%
Nov 13, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line
Aug 12, 2026Downgrade
OPY logoOOppenheimer
Outperform → Perform
Jul 24, 2026Downgrade
UBS logoUUBS
Buy → Neutral$28+73.9%
Jul 13, 2026Resumed
JPM logoJJP Morgan
Neutral$35+117.4%
Feb 12, 2026Downgrade
RRothschild & Co Redburn
Buy → Neutral$24+49.1%
Jan 22, 2026Downgrade
TD logoTTD Cowen
Buy → Hold$21+30.4%
Jan 07, 2026Initiated
OPY logoOOppenheimer
Outperform$75+365.8%
Oct 07, 2025Initiated
CCantor Fitzgerald
Overweight$40+148.4%
Oct 08, 2024Initiated
RRedburn Atlantic
Buy$86+434.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanders Corazon (Corsee) D.DirectorSep 29 '26Sale9.4627,370258,92052,731Oct 01 04:04 PM
Sanders Corazon (Corsee) D.DirectorSep 29 '26Proposed Sale18.9213,685258,915Sep 29 02:31 PM
Santos Carlos EChief Financial OfficerSep 21 '26Sale9.145,43049,63014,246Sep 23 04:15 PM
Santos Carlos EOfficerSep 22 '26Proposed Sale18.732,71550,854Sep 22 03:30 PM
Huang YingFormer Officer & DirectorSep 22 '26Proposed Sale18.6569,8121,302,109Sep 22 02:33 PM
Casey Patrick JohnDirectorJun 30 '26Proposed Sale29.603,00088,800Jun 30 10:46 AM
Huang YingChief Executive OfficerJun 25 '26Sale14.785,56682,265241,872Jun 29 09:53 PM
Huang YingOfficerJun 26 '26Proposed Sale28.392,78379,017Jun 26 03:23 PM
Huang YingChief Executive OfficerMar 25 '26Sale8.779,93687,139247,438Mar 27 04:25 PM
Huang YingOfficerMar 26 '26Proposed Sale17.544,96887,149Mar 26 04:27 PM
Yeung JessieOfficerMar 26 '26Proposed Sale17.541,86232,663Mar 26 04:20 PM
Huang YingOfficerDec 26 '25Proposed Sale22.5264,3391,449,074Dec 29 07:28 AM
Sanders Corazon (Corsee) D.DirectorDec 24 '25Proposed Sale22.7796922,064Dec 29 06:45 AM
Huang YingOfficerDec 24 '25Proposed Sale22.9561,4671,410,606Dec 29 06:40 AM
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Bridgewater, NJ.
Chief Executive OfficerMs. Ingrid Zhang
Chief Financial OfficerMr. Carlos Santos Garcia
J.D.Ms. Ananda Elizabeth Martin Esq.
General CounselMr. Robert Staloff
Interim Head of Research & Development and Senior VP of Regulatory AffairsDr. Yuhong Qiu Ph.D.